AstraZeneca Looks To FluMist Experience In COVID-19 Efforts
The UK firm speaks about its efforts to tackle the virus as a recent spike in COVID-19 cases outside China heighten concerns.
You may also be interested in...
Companies continue to throw their hats into the ring against the virus, with strategies ranging from ‘off the shelf’ molecules to novel vaccine and anti-viral therapies
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.